Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2025-11-05 00:00:00 ET · period of report 2025-11-03 · accession 0002065881-25-000035 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-05 | 2025-11-03 | ARQT | Vairavan Latha | SVP CFO | S - Sale | $24.72 | -88 | 64.9K | -0.1% | -$2,175 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-03 | S | D | 88 | $24.72 | 64,927 | D | — | — | (F2) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.435 to $25.31, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |